NEWS
ReShape Lifesciences® Enters Into Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys
ReShape Lifesciences has entered into a merger agreement with Vyome Therapeutics and an asset purchase agreement with Biorad Medisys for $5.16 million.
The all-stock merger will see Vyome and ReShape combine, focusing on immuno-inflammatory diseases. Post-merger, ReShape will be renamed Vyome Holdings and will trade under the Nasdaq ticker 'HIND'.
ReShape's assets, including the Obalon Gastric Balloon System, will be sold to Biorad, with Biorad assuming most liabilities.
ReShape and Vyome secured commitments for $7.3 million in investments. The merger requires approval from ReShape's stockholders and various regulatory bodies.
The all-stock merger will see Vyome and ReShape combine, focusing on immuno-inflammatory diseases. Post-merger, ReShape will be renamed Vyome Holdings and will trade under the Nasdaq ticker 'HIND'.
ReShape's assets, including the Obalon Gastric Balloon System, will be sold to Biorad, with Biorad assuming most liabilities.
ReShape and Vyome secured commitments for $7.3 million in investments. The merger requires approval from ReShape's stockholders and various regulatory bodies.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment